AKO-A vs. CPRX
AKO-A (Embotelladora Andina S.A) and CPRX (Catalyst Pharmaceuticals, Inc.) are both stocks. AKO-A operates in Beverages - Non-Alcoholic (Consumer Defensive), while CPRX operates in Biotechnology (Healthcare). Over the past 10 years, AKO-A returned 10.38%/yr vs 46.44%/yr for CPRX. At a 0.04 correlation, their price movements are largely independent.
Performance
AKO-A vs. CPRX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, AKO-A achieves a 4.44% return, which is significantly lower than CPRX's 34.06% return. Over the past 10 years, AKO-A has underperformed CPRX with an annualized return of 10.38%, while CPRX has yielded a comparatively higher 46.44% annualized return.
AKO-A
- 1D
- 0.00%
- 1M
- 7.87%
- YTD
- 4.44%
- 6M
- 9.00%
- 1Y
- 18.97%
- 3Y*
- 32.73%
- 5Y*
- 25.60%
- 10Y*
- 10.38%
CPRX
- 1D
- 0.03%
- 1M
- 1.39%
- YTD
- 34.06%
- 6M
- 35.57%
- 1Y
- 23.72%
- 3Y*
- 39.44%
- 5Y*
- 41.69%
- 10Y*
- 46.44%
AKO-A vs. CPRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
AKO-A Embotelladora Andina S.A | 4.44% | 69.94% | 22.39% | 32.28% | 25.25% | -15.56% | -9.03% | -14.12% | -25.96% | 33.08% |
CPRX Catalyst Pharmaceuticals, Inc. | 34.06% | 11.84% | 24.15% | -9.62% | 174.74% | 102.69% | -10.93% | 95.31% | -50.90% | 272.38% |
Correlation
The correlation between AKO-A and CPRX is -0.02, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.02 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.01 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.05 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.05 |
Correlation (All Time) Calculated using the full available price history since Nov 9, 2006 | 0.04 |
Fundamentals
AKO-A:
$3.55B
CPRX:
$3.97B
AKO-A:
$1.95K
CPRX:
$1.74
AKO-A:
0.01
CPRX:
17.98
AKO-A:
0.00
CPRX:
0.32
AKO-A:
0.00
CPRX:
6.67
AKO-A:
0.00
CPRX:
3.92
AKO-A:
$3.42T
CPRX:
$596.96M
AKO-A:
$1.34T
CPRX:
$378.23M
AKO-A:
$620.88B
CPRX:
$313.50M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
AKO-A vs. CPRX — Risk / Return Rank
AKO-A
CPRX
AKO-A vs. CPRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Embotelladora Andina S.A (AKO-A) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| AKO-A | CPRX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.33 | ||
| Sortino ratioReturn per unit of downside risk | -0.27 | ||
| Omega ratioGain probability vs. loss probability | 1.13 | 1.15 | -0.02 |
| Calmar ratioReturn relative to maximum drawdown | 1.07 | 0.87 | +0.19 |
| Martin ratioReturn relative to average drawdown | 2.07 | 1.59 | +0.48 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| AKO-A | CPRX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.38 | 0.71 | -0.33 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.61 | 0.88 | -0.26 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.25 | 0.77 | -0.52 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.21 | 0.09 | +0.12 |
Drawdowns
AKO-A vs. CPRX - Drawdown Comparison
The maximum AKO-A drawdown since its inception was -79.18%, smaller than the maximum CPRX drawdown of -94.25%. Use the drawdown chart below to compare losses from any high point for AKO-A and CPRX.
Loading charts...
Drawdown Indicators
| AKO-A | CPRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -79.18% | -94.25% | +15.07% |
Max Drawdown (1Y)Largest decline over 1 year | -17.84% | -27.29% | +9.45% |
Max Drawdown (3Y)Largest decline over 3 years | -25.41% | -27.29% | +1.88% |
Max Drawdown (5Y)Largest decline over 5 years | -25.41% | -45.37% | +19.96% |
Max Drawdown (10Y)Largest decline over 10 years | -63.51% | -64.87% | +1.36% |
Current DrawdownCurrent decline from peak | -9.73% | -0.13% | -9.60% |
Average DrawdownAverage peak-to-trough decline | -30.92% | -52.04% | +21.12% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.25% | 14.95% | -5.70% |
Volatility
AKO-A vs. CPRX - Volatility Comparison
Embotelladora Andina S.A (AKO-A) has a higher volatility of 10.46% compared to Catalyst Pharmaceuticals, Inc. (CPRX) at 2.45%. This indicates that AKO-A's price experiences larger fluctuations and is considered to be riskier than CPRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| AKO-A | CPRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.46% | 2.45% | +8.01% |
Volatility (6M)Calculated over the trailing 6-month period | 39.94% | 23.57% | +16.37% |
Volatility (1Y)Calculated over the trailing 1-year period | 50.65% | 33.60% | +17.05% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 42.02% | 47.86% | -5.84% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 41.81% | 60.59% | -18.78% |
Dividends
AKO-A vs. CPRX - Dividend Comparison
AKO-A's dividend yield for the trailing twelve months is around 4.37%, while CPRX has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AKO-A Embotelladora Andina S.A | 4.37% | 5.24% | 6.95% | 9.27% | 17.81% | 8.12% | 5.74% | 4.72% | 4.16% | 2.63% | 2.34% | 2.50% |
CPRX Catalyst Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
AKO-A vs. CPRX - Financials Comparison
This section allows you to compare key financial metrics between Embotelladora Andina S.A and Catalyst Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
AKO-A vs. CPRX - Profitability Comparison
AKO-A - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Embotelladora Andina S.A reported a gross profit of 393.07B and revenue of 958.49B. Therefore, the gross margin over that period was 41.0%.
CPRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 149.39M. Therefore, the gross margin over that period was 0.0%.
AKO-A - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Embotelladora Andina S.A reported an operating income of 147.46B and revenue of 958.49B, resulting in an operating margin of 15.4%.
CPRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported an operating income of 73.23M and revenue of 149.39M, resulting in an operating margin of 49.0%.
AKO-A - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Embotelladora Andina S.A reported a net income of 102.93B and revenue of 958.49B, resulting in a net margin of 10.7%.
CPRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a net income of 63.73M and revenue of 149.39M, resulting in a net margin of 42.7%.
Frequently Asked Questions
AKO-A and CPRX have a correlation of -0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
AKO-A has higher volatility (10.46%) compared to CPRX (2.45%). In terms of maximum drawdown, AKO-A dropped -79.18% vs CPRX's -94.25%.
CPRX currently has the higher Sharpe Ratio (0.71 vs 0.38), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for AKO-A and CPRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer